Biogen stock falls after FDA calls for federal investigation into Alzheimer’s drug approval - Earth News Report
In this articleBIIBA sign marks a Biogen facility, in Cambridge, Massachusetts, March 9, 2020.Brian Snyder | ReutersBiogen shares fell on Friday after the head of the Food and Drug Administration called for an investigation into the recent approval of the company's Alzheimer's drug, Aduhelm.In a letter dated and made public Friday, Acting FDA Commissioner Dr.
